Rheumatoid arthritis (RA) is an autoimmune disease that involves multiple joints bilaterally.
It is characterized by an inflammation of the tendon (tenosynovitis) resulting in both cartilage …

The development of biologics and small oral molecules has recently changed the scenario
of pharmacologic treatment of systemic rheumatic diseases and it has become a real …

Introduction: Biosimilar medicines are considered promising alternatives to new biologicals
with high price tags. The extent of savings resulting from biosimilar use depends on their …

The results from ongoing natural history and prevention trials in RA should further inform
several critical issues in RA prevention including identification and enrolment of individuals …

Introduction: Little is known about market access to biosimilars from a health economic
perspective, except for studies that compute the budget impact of biosimilar use. Areas …

The development of biological disease-modifying antirheumatic drugs (bDMARDs) and
target synthetic DMARDs (tsDMARDs), also known as small molecule inhibitors, represent a …

Objective In this systematic review on drug price comparison studies, we report on recent
determinants of drug prices in a national and international context to facilitate regulation of …

Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease. Despite the wide
use of conventional synthetic, targeted and biologic disease modifying anti-rheumatic drugs …

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease of unknown cause. The
interaction of immune system cells and the secretion of inflammatory cytokines with synovial …

Introduction Pharmaceutical systems are frequently characterized by fragmentation, and
competences for outpatient and inpatient sectors sit with different authorities, payers, and …